



# Projects supported by DHSC through the UK Vaccine Network

**Last updated February 2019**

Published 28 August 2019

The following document includes all projects currently funded by the UK Vaccine Network

## Contents

Projects funded through the Innovate UK £10m Vaccine Development Competition .....	2
Projects supported through MRC/BBSRC Centres of Excellence, managed through the National Institute for Health Research .....	5
Projects funded through Innovate UK competition to develop candidate vaccines and vaccine platform technologies at the preclinical stage – Stage 1 (projects now finished) ....	6
Projects funded through Innovate UK competition to develop candidate vaccines and vaccine platform technologies at the preclinical stage – Stage 2.....	8
Projects funded through Innovate UK competition to develop candidate vaccines and vaccine platform technologies at the clinical stage .....	9
Project funded through Engineering and Physical Sciences Research Council (EPSRC) Future Manufacturing Research Hub competition.....	10
Projects funded through Biotechnology and Biological Sciences Research Council (BBSRC) ‘One Health’ competition .....	11
Projects funded through National Institute for Health Research ‘Epidemiology for Vaccinology’ competition .....	12

# Projects funded through the Innovate UK £10m Vaccine Development Competition

This Innovate UK Competition was split into 3 parts:

- Stage 1, Stream 1 – smaller awards to support proposals that are at an earlier stage of development
- Stage 1, Stream 2 – larger awards for projects that are at a more advanced stage of development and are likely to go into Phase I first-in-human trials within the next 12 months
- Stage 2, Stream 1 – further, larger awards for projects successful at Stage 1, Stream 1 and ready for more advanced development

## Stage 1, Stream 1 (projects now finished)

Project Title	Lead Bidder	Cost
Protective efficacy and neutralisation to select an optimal Zika virus vaccine	Jenner Institute, Oxford University	£498,870
Differential diagnostics of haemorrhagic fevers in resource poor environments	BG Research Ltd	£654,717
Improved Q Fever Vaccine	Mologic Ltd	£522,800
An Oral Zika Vaccine	Stabilitech Limited	£214,270
A Conditional System for Inexpensive Manufacture of Attenuated Vaccines	Plymouth University	£156,181
Polyhedrin-encased glycoproteins as novel cold chain independent vaccines	Cell Guidance Systems	£486,701
An affordable, oral vaccine against mosquito- and sexually-transmitted Zika virus	Prokarium Ltd	£394,407
LassaVacc	Public Health England	£593,928
A Dengue/Zika Vaccine That Avoids Antibody-Dependent Enhancement	Excivion Ltd	£500,000
Room temperature stable Modified Vaccinia Ankara (MVA)- glycoprotein pox vectored vaccine against Crimean-Congo Haemorrhagic Fever	Nova Biopharma Technologies Ltd	£428,646

Projects supported by DHSC through the UK Vaccine Network

<b>Project Title</b>	<b>Lead Bidder</b>	<b>Cost</b>
Emerging Viral Vaccine Antigen Insert Consortium (EVAC)	University of Cambridge	£498,379
Development of an economically viable CCHF virus vaccine for local production	Oxford Expression Technologies Ltd	£217,428
Self-administered vaccines directed against Plague and Middle East Respiratory Syndrome (MERS)	Proxima Concepts Limited	£495,000
Development of a novel vaccine for rapid response against Plague	Oxford Vaccine Group, University of Oxford	£359,777
'Plug and Display' virus-like particle platform for rapid response vaccination	Jenner Institute, University of Oxford	£394,427
		Total – £6,415,531

**Stage 1, Stream 2**

<b>Project Title</b>	<b>Lead Bidder</b>	<b>Cost</b>
Development of a single dose ambient temperature stable vaccine for the prevention of Zika virus	Themis Ltd	£999,180
Rapid, simple manufacture and clinical evaluation of an oral plague vaccine	Prokarium Ltd	£1,035,557
A phase I clinical trial of a Chikungunya vaccine using a single dose and no adjuvant	Jenner Institute, University of Oxford	£976,757
Phase I Study of a Modified Vaccinia Ankara (MVA) based vaccine for Crimean Congo Haemorrhagic fever	Public Health England	£1,041,860
Addressing Efficacy of a Dengue vaccine candidate in a macaque challenge model	Jenner Institute, University of Oxford	£488,611
		Total - £4,541,965

## Stage 2, Stream 1

<b>Project Title</b>	<b>Lead Bidder</b>	<b>Cost</b>
An Oral Zika Vaccine	Stabilitech Biopharma Limited	£1,998,148
Development of an economically viable CCHF virus vaccine	Oxford Expression Technologies Ltd	£2,000,000
Clinical Development of a Zika Vaccine Avoiding Disease Enhancement	Excivion Ltd	£2,000,000
Improved Q Fever vaccine (DSTL, PHE, ICENI DX & Mologic)	Mologic	£1,642,392
		Total - £7,640,540

## Projects supported through MRC/BBSRC Centres of Excellence, managed through the National Institute for Health Research

Project Title	Lead Bidder	Cost
Phase I studies of a novel chimpanzee adenovirus MERS vaccine	MRC Centre for Human Immunology, University of Oxford, with Jenner Institute, University of Oxford	£1,866,981
Phase I studies of a novel chimpanzee adenovirus Rift Valley Fever vaccine for humans	MRC Uganda Virus Research Institute, with Jenner Institute, University of Oxford and Pirbright Institute	£1,870,492
Design, development, GMP manufacture and Phase I trials of a Zika vaccine	Centre for Virus Research, University of Glasgow with Jenner Institute, University of Oxford	£2,343,762
Advanced development of a safe and effective CCHF vaccine for livestock and humans	Pirbright Institute and Public Health England	£2,468,495
Advanced development of a safe and effective Rift Valley Fever vaccine for livestock	Pirbright Institute with Jenner Institute, University of Oxford and International Livestock Research Institute, Nairobi	£1,886,544
A platform for the rapid development and production of candidate vaccines, analytical and diagnostic standards by plant-based transient expression for response to global viral threats	John Innes Centre	£1,591,073
		Total - £12,027,347

# Projects funded through Innovate UK competition to develop candidate vaccines and vaccine platform technologies at the preclinical stage – Stage 1 (projects now finished)

Project Title	Lead bidder	Cost
EML-VAC: Multivalent replicon vaccine against Ebola, Marburg and Lassa viruses	Imperial College	£492,527
Exploitation of x-ray irradiated viruses for vaccine development (focussed on Rift Valley Fever)	Public Health England	£452,324
A novel diagnostic for anti-Zika antibodies to inform deployment of Zika vaccines	Excivion Ltd	£500,000
Novel multivalent vaccines against haemorrhagic fevers	Jenner Institute	£483,455
Trivalent Lassa, Ebola and Marburg viral vaccine (Tri-LEMvac)	University of Cambridge	£695,639
Validation and cGMP manufacture of a Zika and Multivalent Filovirus vaccine	Emergex Vaccines	£499,825
Development of Virus-Like Particles as vaccines against emerging viral diseases (focussed on Chikungunya and Rift Valley Fever)	Leaf Systems International Limited	£490,375
Multivalent Attenuated Vaccine against Viral and Bacterial Zoonoses in Ruminants (Developing multivalent vaccine against Rift Valley Fever and Q Fever)	Plymouth University	£408,589
Development of a novel vaccine to protect against Q fever epidemics	Oxford Vaccine Group	£469,049
A novel livestock vaccination platform to prevent zoonotic emerging infections (focussed on Q Fever, Rift Valley Fever and CCHF)	University of Edinburgh	£327,239

Projects supported by DHSC through the UK Vaccine Network

<b>Project Title</b>	<b>Lead bidder</b>	<b>Cost</b>
Nanoparticle-based Vaccine Platform against Zika Virus Infection	Vaxinano	£208,500
Development of inducible expression-inactivated Leishmania as vaccine carrier (focussed on developed a multivalent vaccine against Ebola, Marburg and Lassa)	Genefirst ltd	£499,000
Preclinical Crimean Congo Haemorrhagic Fever Vaccine Development	Jenner Institute	£350,780
New Application of a DNA-nanorod Platform for Vaccine Development	University of Strathclyde	£394,466
Multivalent Hantavirus-Vaccine (MVA SEO-HTN: Vacc) and a ferret model of disease	Public Health England	£476,102
Pan-filovirus T-cell Vaccine Designed as Bi-valent Conserved Region Epigraphs	Jenner Institute	£499,15
Development of a novel Nipah Virus pre-fusion protein recombinant vaccine	Agri-Food and Biosciences Institute	£271,373
Preclinical PoC of multivalent vaccine agents & technology platform (focussed on vaccines for Chikungunya, Zika and Ebola)	Activirosomes UK Limited	£448,950
Using engineered gut bacteria-derived microvesicles for Plague vaccines	UEA	£499,798
Serological Vaccine Standards for Ebola, Zika and MERS	NIBSC	£499,995
Adjuvant free vaccines and companion diagnostics to control emerging flaviviruses (focussed on Zika)	Liverpool School of Tropical Medicine	£382,974
Guillain Barre syndrome antibodies during Zika and Chikungunya vaccine trials	Imperial College	£271,764
		Total – £9,621,879

# Projects funded through Innovate UK competition to develop candidate vaccines and vaccine platform technologies at the preclinical stage – Stage 2

Project Title	Lead bidder	Cost
Serological Vaccine Standards for Emerging Diseases	NIBSC	£1,999,053
CCHF Vaccine manufacturing and First in Human Clinical Trial	Jenner Institute, University of Oxford	£1,999,524
Clinical Stage multivalent vaccines against viral haemorrhagic fevers	Jenner Institute, University of Oxford	£1,999,320
Clinical trial of a DIOS Trivalent Haemorrhagic Fever Vaccine (DIOS-HFVac3)	University of Cambridge	£1,999,926
EML-VAC: Multivalent replicon vaccine against Ebola, Marburg and Lassa viruses	Imperial College	£1,999,713
Advancement of a cost-effective MVA-based Hantavirus vaccine (HantaVacc)	Public Health England	£2,000,000
Development of a novel vaccine to protect against Q fever epidemics: late stage preclinical formulation and progression to clinical trial	Oxford Vaccine Group	£1,054,907
		Total - £13,052,443

# Projects funded through Innovate UK competition to develop candidate vaccines and vaccine platform technologies at the clinical stage

Project Title	Lead bidder	Cost
Identification & Validation of Correlate of Protection for a Chikungunya Vaccine	GreyRigge Associates Ltd	£3,000,000
Ebola vaccines: persistence of immunity & response to booster dose of MVA-EBO Z	University of Oxford	£1,209,548
A phase I study of recombinant poxvirus Zika vaccines	University of Liverpool	£4,716,257
A Nipah vaccine to eliminate porcine reservoirs and safeguard human health	The Pirbright Institute	£2,359,553
Vaccine against mosquito-borne diseases	PepTcell Limited (trading as SEEK)	£3,600,000
Phase Ib trial of a simple, multivalent vaccine to prevent Zika and Chikungunya	The Jenner Institute / University of Oxford	£3,463,676
Clinical development of a new vaccine for rapid response against Plague: GMP production and phase I trial	Oxford Vaccine Group	£2,991,418
		Total - £21,340,452

# Project funded through Engineering and Physical Sciences Research Council (EPSRC) Future Manufacturing Research Hub competition

<b>Project Title</b>	<b>Lead bidder</b>	<b>Cost</b>
Future Vaccine Manufacturing Hub	Imperial College London	£9,947,570
Vax-Hub	University College London	£6,966,745.12
		Total - £16,914,315

# Projects funded through Biotechnology and Biological Sciences Research Council (BBSRC) ‘One Health’ competition

Project Title	Lead bidder	Cost
Accelerated development of a safe and easily manufactured Q fever vaccine	Moredun Research Institute	£1,132,649.50
One Health and accelerating Vaccines for Ebola and Lassa (OVEL)	University of Cambridge	£1,466,336.30
Vaccines and molecular tools for the control of the emerging bunyavirus, severe fever with thrombocytopenia syndrome phlebovirus (SFTSV)	University of Glasgow	£890,279.02
Bunyavirus Immunity Consortium: Delineating the immune response against CCHFV and other Nairoviruses to aid effective vaccine design	University of Oxford	£1,176,386.95
A One Health approach to pan-valent morbillivirus vaccines	University of Glasgow	£761,441.74
		Total - £5,427,094

# Projects funded through National Institute for Health Research ‘Epidemiology for Vaccinology’ competition

Project Title	Lead bidder	Cost
Electronic Data Capture to support rapid epidemiological research and response during epidemics	London School of Hygiene and Tropical Medicine	£539,143.00
Anthropological exploration of facilitators and barriers to vaccine deployment and administration during disease outbreaks	London School of Hygiene and Tropical Medicine	£747,966.00
Leveraging Pathogen Sequence Data and Adaptive Designs to Improve Vaccine Trials in Emerging Epidemics in LMIC	University of Oxford	£744,463.00
Molecular Epidemiology for Vaccination Policy (MEVACP)	University of Oxford	£662,083.00
Vaccine Efficacy Evaluation for Priority Emerging Diseases (VEEPED)	London School of Hygiene and Tropical Medicine	£1,500,000
		Total - £4,193,655